paper_id,claim,figure_id,title,caption,local_image_path,url
PMC7667107,We used the remaining 71 studies that included data of at least one genetic alteration in our final analysis (Figure 1).,PMC7667107_figure_1,Figure 1.,Study flowchart.,./data/PMC7667107/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/fda8c139d23a/gs-09-05-1813-f1.jpg
PMC7667107,Table 2 and Figure 2A show the worldwide frequency of RAS mutation.,PMC7667107_figure_2,Figure 2.,"Global map of RAS mutation (A) and PAX8/PPARγ rearrangement (B) in FTC patients. Countries where the data are unavailable are shown in white. FTC, follicular thyroid carcinoma.",./data/PMC7667107/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg
PMC7667107,"Country/region
No. studies
NRAS
HRAS
KRAS
Any RAS
PAX8/PPARγ

No. with a mutation/total no. [%]



Asia








   China
1 (34)
10/53 [19]
4/53 [8]
3/53 [3]
17/53 [32]
1/53 [2]


   Japan
10 (6,10,16,17,21-26)
63/215 [29]
5/158 [3]
5/173 [3]
73/215 [34]
1/66 [2]


   Korea
8 (5,27-33)
56/246 [23]
21/223 [9]
16/223 [7]
93/246 [38]
5/106 [5]


   Malaysia
1 (35)




2/18 [11]


   Taiwan
1 (36)
1/8 [13]
1/8 [13]
1/8 [13]
3/8 [38]



   Vietnam
1 (10)
4/23 [17]
0/23 [0]
0/23 [0]
4/23 [17]



   India
1 (37)
0/8 [0]
0/8 [0]
0/8 [0]
0/8 [0]



   Overall
23
134/553 [24]
31/473 [7]
25/488 [5]
190/553 [34]
9/243 [4]


Europe








   France
4 (39-42)
9/27 [33]
0/11 [0]
0/6 [0]
9/32 [28]
13/44 [30]


   Germany
3 (43-45)
1/12 [8]
0/12 [0]
0/12 [0]
1/12 [8]
2/40 [5]


   Italy
7 (46-52)
34/146 [23]
8/120 [5]
5/141 [4]
47/146 [32]
2/49 [4]


   Portugal
2 (53,54)
2/25 [8]
1/25 [4]
0/25 [0]
3/25 [12]
13/41 [31]


   Poland
2 (55,56)
2/55 [4]
6/55 [11]
2/55 [4]
10/55 [18]
0/20 [0]


   UK
2 (57,58)
5/19 [26]
3/19 [16]
0/19 [0]
8/19 [42]



   Switzerland
1 (15)




5/31 [16]


   Spain
1 (59)
2/10 [20]
0/10 [0]
0/10 [0]
2/10 [20]



   Turkey
2 (60,61)


0/13 [0]
0/13 [0]
3/9 [33]


   Croatia
1 (62)




7/18 [39]


   Denmark
2 (63,64)
3/24 [13]
1/24 [4]
0/24 [0]
4/24 [17]
7/44 [16]


   Hungary
1 (11)
1/6 [17]
2/6 [33]
0/6 [0]
3/6 [50]



   Norway
1 (65)
2/7 [29]
1/7 [14]

3/7 [43]
0/7 [0]


   Sweden
1 (66)




10/34 [29]


   Overall
30
61/331 [18]
22/289 [8]
7/311 [2]
90/349 [26]
62/337 [18]


North America








   USA
15 (67-81)
26/76 [34]
4/76 [5]
2/86 [2]
57/194 [29]
48/149 [32]


   Canada
1 (11)
0/10 [0]
1/10 [10]
0/10 [0]
1/10 [10]



   Overall
16
26/86 [30]
5/86 [6]
2/96 [2]
58/204 [28]
48/149 [32]


South America








   Brazil
1 (82)




4/13 [31]


   Overall
1




4/13 [31]


Oceania








   Australia
2 (83,84)
5/27 [19]
3/27 [11]
0/27 [0]
8/27 [30]
7/22 [32]


   Overall
2
5/27 [19]
3/27 [11]
0/27 [0]
8/27 [30]
7/22 [32]


Middle East








   Saudi Arabia
1 (38)
1/10 [10]
1/10 [10]
0/10 [0]
2/10 [20]



   Overall
1
1/10 [10]
1/10 [10]
0/10 [0]
2/10 [20]




Open in a new tab
FTC, follicular thyroid carcinoma.Figure 2.",PMC7667107_figure_2,Figure 2.,"Global map of RAS mutation (A) and PAX8/PPARγ rearrangement (B) in FTC patients. Countries where the data are unavailable are shown in white. FTC, follicular thyroid carcinoma.",./data/PMC7667107/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg
PMC7667107,Table 2 and Figure 2B show the frequencies of PAX8/PPARγ rearrangement.,PMC7667107_figure_2,Figure 2.,"Global map of RAS mutation (A) and PAX8/PPARγ rearrangement (B) in FTC patients. Countries where the data are unavailable are shown in white. FTC, follicular thyroid carcinoma.",./data/PMC7667107/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23df/7667107/a141e164bff6/gs-09-05-1813-f2.jpg
